Segment Information - Schedule of Reconciles Segment Direct Profit or Loss (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2026	Sep. 30, 2025	Sep. 30, 2026	Sep. 30, 2025
Segment Reporting [Line Items]
Total research and development	$ 10,824	$ 6,528	$ 32,631	$ 15,720
Total general and administrative	11,902	3,649	26,355	11,578
Loss from operations	(22,726)	(10,177)	(58,986)	(27,298)
QTORIN CMC [Member]
Segment Reporting [Line Items]
Total research and development	2,879	2,265	8,014	4,554
QTORIN Rapamycin for Microcystic LM [Member]
Segment Reporting [Line Items]
Total research and development	480	1,103	2,880	3,492
Qtorin Rapamycin For Angiokeratomas [Member]
Segment Reporting [Line Items]
Total research and development	843	0	2,044	0
QTORIN Rapamycin For Cutaneous VM [Member]
Segment Reporting [Line Items]
Total research and development	156	827	1,313	1,527
QTORIN Rapamycin for Microcystic LM - Government Grant Income [Member]
Segment Reporting [Line Items]
Total research and development	(484)	(53)	(484)	(392)
Salaries and Stock-based Compensation [Member]
Segment Reporting [Line Items]
Total research and development	4,444	1,658	11,331	4,481
Total general and administrative	6,614	2,151	15,044	5,348
Consultants [Member]
Segment Reporting [Line Items]
Total research and development	1,050	414	4,484	1,046
Total general and administrative	3,360	587	6,053	2,497
Other [Member]
Segment Reporting [Line Items]
Total research and development	1,456	314	3,049	1,012
Total general and administrative	$ 1,928	$ 911	$ 5,258	$ 3,733